|
Q3 FY2024
As of Dec 31, 2023
|
Q2 FY2024
As of Sep 30, 2023
|
Q1 FY2024
As of Jun 30, 2023
|
Q4 FY2023
As of Mar 31, 2023
|
Q3 FY2023
As of Dec 31, 2022
|
Q2 FY2023
As of Sep 30, 2022
|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
Q2 FY2022
As of Sep 30, 2021
|
Q1 FY2022
As of Jun 30, 2021
|
Q3 FY2021
As of Dec 31, 2020
|
Q2 FY2021
As of Sep 30, 2020
|
Q1 FY2021
As of Jun 30, 2020
|
Q4 FY2020
As of Mar 31, 2020
|
Q3 FY2020
As of Dec 31, 2019
|
Q2 FY2020
As of Sep 30, 2019
|
Q1 FY2020
As of Jun 30, 2019
|
Q4 FY2019
As of Mar 31, 2019
|
Q3 FY2019
As of Dec 31, 2018
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accounts receivable, net, including related parties (Note 11) | ||||||||||||||||||||
| Accounts receivable, net of allowance for doubtful accounts of $263 and $0 at December 31, 2023 and March 31, 2023, respectively, including related parties (Note 11) | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Investment in joint venture | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable and accrued expenses, including related parties (Note 11) | ||||||||||||||||||||
| Development loan | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Unfunded commitment in joint venture | ||||||||||||||||||||
| Accrued payroll and benefits | ||||||||||||||||||||
| Promissory note | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Revolving credit facility | ||||||||||||||||||||
| Unfunded commitment to joint venture | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Promissory note | ||||||||||||||||||||
| Revolving credit facility, net of current portion | ||||||||||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Common stock, shares authorized (in shares) | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized and none issued and outstanding as of December 31, 2023 and March 31, 2023 | ||||||||||||||||||||
| Common stock, $0.0001 par value; 750,000,000 shares authorized as of December 31, 2023 and March 31, 2023, and 63,195,948 and 57,047,013 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
